AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9459339 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg enalaprilat intravenously prior to thrombolysis
Number of subjects: 23
Study 7629560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (1 g, intramuscularly administered)
Number of subjects: 25
Study 2535067 — intervention group
Group type: EXPERIMENTAL
Intervention: mesoglycan (72 mg/day orally)
Number of subjects: 90
Study 2535067 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 2535067 — intervention group
Group type: EXPERIMENTAL
Intervention: mesoglycan
Number of subjects: 90
Study 31123606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 0
Study 31123606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26755506 — intervention group
Group type: EXPERIMENTAL
Intervention: New sedation policy (sequential administration of melatonin, hydroxyzine, and chloral hydrate)
Number of subjects: 803
Study 26755506 — intervention group
Group type: COMPARATOR
Intervention: Old sedation policy (sole administration of chloral hydrate)
Number of subjects: 803
Study 26755506 — intervention group
Group type: EXPERIMENTAL
Intervention: New sedation policy
Number of subjects: 803
Study 25913070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole (NIM) administered at a dose of 1.2g/m2, 90 minutes before the first daily radiotherapy (RT) fraction.
Number of subjects: 104
Study 25913070 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone.
Number of subjects: 104
Study 23993464 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 54
Study 23993464 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 54
Study 23993464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22004601 — intervention group
Group type: EXPERIMENTAL
Intervention: Full drug-eluting stent (DES) coverage (n = 90)
Number of subjects: 179
Study 22004601 — intervention group
Group type: COMPARATOR
Intervention: Spot drug-eluting stent (DES) coverage (n = 89)
Number of subjects: 179
Study 22004601 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot DES
Number of subjects: 179
Study 22004601 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot DES (after controlling for confounding factors)
Number of subjects: 179
Study 18238861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 0
Study 18238861 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 16608954 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel, 35 mg/m(2) IV infusion (D(35)) on days 1, 8, and 15 every 4 weeks
Number of subjects: 161
Study 16608954 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel, 40 mg/m(2) IV (D(40)) on days 1 and 8 every 3 weeks
Number of subjects: 161
Study 16608954 — intervention group
Group type: COMPARATOR
Intervention: docetaxel, 75 mg/m(2) IV (D(75)) on day 1 every 3 weeks
Number of subjects: 161
Study 14511275 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg dose of eletriptan
Number of subjects: 113
Study 10811333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum (DSM 9843) in a rose-hip drink (400 ml per day, 5 x 10(7) cfu/ml)
Number of subjects: 60
Study 10811333 — intervention group
Group type: COMPARATOR
Intervention: Plain rose-hip drink (control)
Number of subjects: 60
Study 10811333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum (DSM 9843) in a rose-hip drink
Number of subjects: 60
Study 8644026 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoton infusions (30 g/day for 3 days)
Number of subjects: 55
Study 8644026 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipin injected intramuscularly (3 mg/kg for 20 days)
Number of subjects: 55
Study 8644026 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipin injected intravenously (10 mg/kg)
Number of subjects: 55
Study 8644026 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 patients)
Number of subjects: 55
Study 1352245 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol (200 mg b.i.d. for 7 days)
Number of subjects: 10
Study 6432857 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 1
Study 6432857 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 1
Study 6432857 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid
Number of subjects: 1
Study 30696041 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroLactin® (ML)
Number of subjects: 58
Study 30696041 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 58
Study 30368330 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training group
Number of subjects: 20
Study 30368330 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 26152242 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held navigation
Number of subjects: 80
Study 26152242 — intervention group
Group type: COMPARATOR
Intervention: Control (no navigation)
Number of subjects: 80
Study 24467942 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg single dose)
Number of subjects: 75
Study 24467942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 21770829 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment (Group A)
Number of subjects: 85
Study 21770829 — intervention group
Group type: COMPARATOR
Intervention: Control (no melatonin treatment, Group B)
Number of subjects: 85
Study 21147712 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg iron as ferrous sulfate
Number of subjects: 186
Study 21147712 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg iron and 0.4 mg folic acid
Number of subjects: 186
Study 21147712 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg iron, 2.0 mg retinol and 0.4 mg folic acid
Number of subjects: 186
Study 21147712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 16844502 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl N‐formyl aspartamate applied twice daily on the left half of the face
Number of subjects: 29
Study 16844502 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied on the right half of the face
Number of subjects: 29
Study 16844502 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl N‐formyl aspartamate
Number of subjects: 29
Study 14708457 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinidipine (10 mg)
Number of subjects: 60
Study 14708457 — intervention group
Group type: COMPARATOR
Intervention: Quinapril (10 mg)
Number of subjects: 60
Study 11185412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg in fasted state
Number of subjects: 21
Study 11185412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg after a high fat meal
Number of subjects: 21
Study 11185412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 640 mg in fasted state
Number of subjects: 21
Study 11185412 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 640 mg after a high fat meal
Number of subjects: 21
Study 9183304 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, low-cholesterol diet during the dietary intervention
Number of subjects: 86
Study 9183304 — intervention group
Group type: EXPERIMENTAL
Intervention: Switchback to original diet
Number of subjects: 86
Study 1562720 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation therapy (6 days of high-dose cytarabine plus 3 days of amsacrine)
Number of subjects: 224
Study 1562720 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy (2 years of continuous outpatient therapy with cytarabine and 6-thioguanine)
Number of subjects: 224
Study 1562720 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (alloBMT)
Number of subjects: 224
Study 1562720 — intervention group
Group type: COMPARATOR
Intervention: Consolidation therapy
Number of subjects: 224
Study 1562720 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy
Number of subjects: 224
Study 1562720 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloBMT
Number of subjects: 224
Study 4011145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate 0.5% eyedrops
Number of subjects: 20
Study 4011145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4011145 — intervention group
Group type: COMPARATOR
Intervention: Cyclopentolate 0.25% eyedrops
Number of subjects: 20
Study 31601494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (15-mg IV every 6 hours)
Number of subjects: 100
Study 31601494 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1-g IV every 6 hours)
Number of subjects: 100
Study 29023185 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Laser Therapy (LLLT) - InGaAlP, λ 660 nm, energy density 6 J/cm2, applied daily from the first to the fourth postoperative day.
Number of subjects: 40
Study 29023185 — intervention group
Group type: COMPARATOR
Intervention: Placebo Group (PG)
Number of subjects: 40
Study 26660143 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (single regimen, baseline only)
Number of subjects: 404
Study 26660143 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (monthly regimen, baseline, weeks 4, 8)
Number of subjects: 404
Study 26660143 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (early regimen, baseline, weeks 1, 2, 4)
Number of subjects: 404
Study 26660143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 24512609 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractor-filtering during encoding
Number of subjects: 3268
Study 24512609 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractor-filtering during maintenance
Number of subjects: 3268
Study 24512609 — intervention group
Group type: COMPARATOR
Intervention: No distractors
Number of subjects: 3268
Study 23231928 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus nurse-delivered telephone coaching
Number of subjects: 168
Study 23231928 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy only
Number of subjects: 168
Study 20334980 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion (Cyberball condition)
Number of subjects: 89
Study 20334980 — intervention group
Group type: COMPARATOR
Intervention: Inclusion (Cyberball condition)
Number of subjects: 89
Study 20334980 — intervention group
Group type: COMPARATOR
Intervention: Technical default (Cyberball condition)
Number of subjects: 89
Study 17029788 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and advice
Number of subjects: 0
Study 17029788 — intervention group
Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 0
Study 16585986 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% Tacrolimus gel
Number of subjects: 124
Study 16585986 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Tacrolimus cream
Number of subjects: 124
Study 16585986 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol ointment
Number of subjects: 124
Study 16585986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus gel and cream
Number of subjects: 124
Study 14644852 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 7
Study 14644852 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 7
Study 14644852 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol recommended
Number of subjects: 7
Study 10991830 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg
Number of subjects: 12
Study 10991830 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg
Number of subjects: 12
Study 10991830 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin 600 mg
Number of subjects: 12
Study 10991830 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg
Number of subjects: 12
Study 10991830 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 12
Study 10991830 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 200 mg
Number of subjects: 12
Study 8834029 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100-micrograms/h infusion after a 100-micrograms bolus)
Number of subjects: 29
Study 8834029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1410154 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (first dose)
Number of subjects: 13
Study 1410154 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (second and third doses)
Number of subjects: 13
Study 1410154 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum condition
Number of subjects: 13
Study 3907259 — intervention group
Group type: EXPERIMENTAL
Intervention: Single instillation of 0.85% cyclopentolate + 1.5% phenylephrine
Number of subjects: 40
Study 3907259 — intervention group
Group type: COMPARATOR
Intervention: Atropine eye drops applied twice a day for 3.5 days
Number of subjects: 40
Study 30219459 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunlight exposure with vitamin D supplementation (20,000 IU weekly)
Number of subjects: 52
Study 30219459 — intervention group
Group type: COMPARATOR
Intervention: Sunlight exposure alone
Number of subjects: 52
Study 30219459 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Sunlight exposure and Sunlight exposure with vitamin D supplementation)
Number of subjects: 52
Study 27569841 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin/ezetimibe
Number of subjects: 1684
Study 27569841 — intervention group
Group type: COMPARATOR
Intervention: simvastatin/placebo
Number of subjects: 1684
Study 24731384 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle (SB) technique
Number of subjects: 50
Study 24731384 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) technique
Number of subjects: 50
Study 22497677 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol 10 mg/day
Number of subjects: 27
Study 22497677 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 19755497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bike Smart program (eHealth software program)
Number of subjects: 206
Study 19755497 — intervention group
Group type: COMPARATOR
Intervention: Control condition (a video on childhood safety)
Number of subjects: 206
Study 18325025 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (Cebrolux-Tubilux, Italy, 1600 mg/diem for 60 days)
Number of subjects: 26
Study 18325025 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 26
Study 16091759 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel
Number of subjects: 283
Study 16091759 — intervention group
Group type: COMPARATOR
Intervention: sequential methotrexate‐fluorouracil (MF)
Number of subjects: 283
Study 12360462 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (beta-blockers and nitrates)
Number of subjects: 102
Study 12360462 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic banding
Number of subjects: 102
Study 10858764 — intervention group
Group type: EXPERIMENTAL
Intervention: Examiners' training programme with pictorial handout and two one-hour diagnostic seminars
Number of subjects: 5
Study 10858764 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 5
Study 8708716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (40 mg/m2) added to high-dose infusional 5-FU (60 mg/kg over 48 hours) given weekly for 4 weeks and thereafter every 2 and 3 weeks.
Number of subjects: 310
Study 8708716 — intervention group
Group type: COMPARATOR
Intervention: High-dose infusional 5-FU without low-dose methotrexate.
Number of subjects: 310
Study 8708716 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose infusional 5-FU with low-dose methotrexate.
Number of subjects: 310
Study 1894476 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral color contrast test for glaucoma patients
Number of subjects: 45
Study 1894476 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral color contrast test for ocular hypertensive patients
Number of subjects: 45
Study 1894476 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk ocular hypertensive patients
Number of subjects: 45
Study 6756933 — intervention group
Group type: EXPERIMENTAL
Intervention: muzolimine (35 +/- 2 mg/day for six weeks)
Number of subjects: 18
Study 6756933 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 31566689 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced tablet-based book
Number of subjects: 37
Study 31566689 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic tablet-based book
Number of subjects: 37
Study 31566689 — intervention group
Group type: COMPARATOR
Intervention: Print book
Number of subjects: 37
Study 28459925 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 300
Study 28459925 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 300
Study 25321146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg twice daily
Number of subjects: 30
Study 25321146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23195283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Number of subjects: 2444
Study 23195283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100mg
Number of subjects: 2444
Study 23195283 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 2444
Study 21651819 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-fracture clinic intervention
Number of subjects: 130
Study 21651819 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study 18837701 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ellagic acid
Number of subjects: 30
Study 18837701 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant extract containing natural ellagic acid
Number of subjects: 30
Study 18837701 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbutin
Number of subjects: 30
Study 17139639 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral graded activity (BGA)
Number of subjects: 200
Study 17139639 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC; exercise therapy and advice)
Number of subjects: 200
Study 12629448 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional insulin therapy with short-acting insulin analog
Number of subjects: 110
Study 10729293 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with complete posterior cortical vitreous peeling
Number of subjects: 102
Study 10729293 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy with peeling of the posterior hyaloid in the area of the macula without complete posterior vitreous detachment
Number of subjects: 102
Study 8940672 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream 0.15%
Number of subjects: 0
Study 8940672 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream 0.3%
Number of subjects: 0
Study 8940672 — intervention group
Group type: COMPARATOR
Intervention: Podophyllotoxin solution 0.5%
Number of subjects: 0
Study 8940672 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream 0.15% (female)
Number of subjects: 0
Study 8940672 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream 0.3% (female)
Number of subjects: 0
Study 8940672 — intervention group
Group type: COMPARATOR
Intervention: Podophyllotoxin solution 0.5% (female)
Number of subjects: 0
Study 1527313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 micrograms once a day
Number of subjects: 313
Study 1527313 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray 168 micrograms twice a day
Number of subjects: 313
Study 1527313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 3873880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (n = 12)
Number of subjects: 33
Study 3873880 — intervention group
Group type: COMPARATOR
Intervention: Metocurine (n = 9)
Number of subjects: 33
Study 3873880 — intervention group
Group type: COMPARATOR
Intervention: Metocurine-pancuronium combination (4:1 ratio by weight) (n = 12)
Number of subjects: 33
Study 31144825 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMI) consisting of a single 45- to 60-min session
Number of subjects: 228
Study 31144825 — intervention group
Group type: EXPERIMENTAL
Intervention: More experienced therapists conducting BMIs
Number of subjects: 228
Study 29997032 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude spinal manipulation (HVLA SM)
Number of subjects: 111
Study 29997032 — intervention group
Group type: COMPARATOR
Intervention: Side-posture positioning
Number of subjects: 111
Study 29997032 — intervention group
Group type: COMPARATOR
Intervention: Joint preloading with no thrust
Number of subjects: 111
Study 27378733 — intervention group
Group type: EXPERIMENTAL
Intervention: Home- and community-based exercise program (12 weeks, with once-weekly telephone or e-mail support)
Number of subjects: 20
Study 27378733 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study 25637265 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (a partial 5-HT1A receptor agonist)
Number of subjects: 0
Study 25637265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25637265 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study 23898485 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 28
Study 21138709 — intervention group
Group type: COMPARATOR
Intervention: 0.0 g/kg alcohol dose
Number of subjects: 187
Study 21138709 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 g/kg alcohol dose
Number of subjects: 187
Study 21138709 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g/kg alcohol dose
Number of subjects: 187
Study 21138709 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol dose
Number of subjects: 187
Study 21138709 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 g/kg alcohol dose
Number of subjects: 187